Open Access Articles- Top Results for ABT-418


Systematic (IUPAC) name
Clinical data
147402-53-7 7pxN
PubChem CID 119380
ChemSpider 106627 7pxY
ChEMBL CHEMBL274525 7pxY
Chemical data
Formula C9H14N2O
 14pxN (what is this?)  (verify)

ABT-418 is a drug developed by Abbott, that has nootropic, neuroprotective and anxiolytic effects,[1][2][3][4] and has been researched for treatment of both Alzheimer's disease[5] and ADHD.[6][7][8] It acts as an agonist at neural nicotinic acetylcholine receptors, subtype-selective binding with high affinity to the α4β2, α7/5-HT3, and α2β2 nicotinic acetylcholine receptors but not the α3β4 subtype[9][10] familiar to nicotine. ABT-418 was reasonably effective for both applications and fairly well tolerated, but produced some side effects, principally nausea, and it is unclear whether ABT-418 itself will proceed to clinical development or if another similar drug will be used instead.[11]

See also


  1. ^ Arneric SP, Sullivan JP, Briggs CA, Donnelly-Roberts D, Anderson DJ, Raszkiewicz JL, Hughes ML, Cadman ED, Adams P, Garvey DS' (July 1994). "(S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: I. In vitro characterization". J. Pharmacol. Exp. Ther. 270 (1): 310–8. PMID 7518514. 
  2. ^ Decker MW, Brioni JD, Sullivan JP, Buckley MJ, Radek RJ, Raszkiewicz JL, Kang CH, Kim DJ, Giardina WJ, Wasicak JT (July 1994). "(S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization". J. Pharmacol. Exp. Ther. 270 (1): 319–28. PMID 7913497. 
  3. ^ Brioni JD, O'Neill AB, Kim DJ, Buckley MJ, Decker MW, Arneric SP (October 1994). "Anxiolytic-like effects of the novel cholinergic channel activator ABT-418". J. Pharmacol. Exp. Ther. 271 (1): 353–61. PMID 7965735. 
  4. ^ Prendergast MA; Terry AV; Jackson WJ et al. (April 1997). "Improvement in accuracy of delayed recall in aged and non-aged, mature monkeys after intramuscular or transdermal administration of the CNS nicotinic receptor agonist ABT-418". Psychopharmacology (Berl.) 130 (3): 276–284. PMID 9151363. doi:10.1007/s002130050240. 
  5. ^ Potter A, Corwin J, Lang J, Piasecki M, Lenox R, Newhouse PA (March 1999). "Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease". Psychopharmacology (Berl.) 142 (4): 334–342. PMID 10229057. doi:10.1007/s002130050897. 
  6. ^ Wilens TE, Biederman J, Spencer TJ, Bostic J, Prince J, Monuteaux MC, Soriano J, Fine C, Abrams A, Rater M, Polisner D (December 1999). "A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder". Am J Psychiatry 156 (12): 1931–7. PMID 10588407. 
  7. ^ Horrigan JP (April 2001). "Present and future pharmacotherapeutic options for adult attention deficit/hyperactivity disorder". Expert Opin Pharmacother 2 (4): 573–586. PMID 11336608. doi:10.1517/14656566.2.4.573. 
  8. ^ Spencer T, Biederman J (2002). "Non-stimulant treatment for Attention-Deficit/Hyperactivity Disorder". J Atten Disord. 6 Suppl 1: S109–19. PMID 12685525. 
  9. ^ Papke RL, Thinschmidt JS, Moulton BA, Meyer EM, Poirier A (February 1997). "Activation and inhibition of rat neuronal nicotinic receptors by ABT-418". Br. J. Pharmacol. 120 (3): 429–438. PMC 1564486. PMID 9031746. doi:10.1038/sj.bjp.0700930. 
  10. ^ Briggs CA, McKenna DG, Piattoni-Kaplan M (June 1995). "Human alpha 7 nicotinic acetylcholine receptor responses to novel ligands". Neuropharmacology 34 (6): 583–590. PMID 7566493. doi:10.1016/0028-3908(95)00028-5. 
  11. ^ Wilens TE, Decker MW (October 2007). "Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: focus on cognition". Biochem. Pharmacol. 74 (8): 1212–1223. PMC 2974320. PMID 17689498. doi:10.1016/j.bcp.2007.07.002. 

Template:Navbox with collapsible sections

Lua error in package.lua at line 80: module 'Module:Buffer' not found.